- Home
- IRD vs ALGS Comparison
IRD vs ALGS Comparison
Compare IRD & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRD
- ALGS
- Stock Information
- Founded
- IRD 2018
- ALGS 2018
- Country
- IRD United States
- ALGS United States
- Employees
- IRD N/A
- ALGS N/A
- Industry
- IRD
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- IRD
- ALGS Health Care
- Exchange
- IRD NYSE
- ALGS Nasdaq
- Market Cap
- IRD 35.7M
- ALGS 38.8M
- IPO Year
- IRD N/A
- ALGS 2020
- Fundamental
- Price
- IRD $0.93
- ALGS $10.28
- Analyst Decision
- IRD Strong Buy
- ALGS Strong Buy
- Analyst Count
- IRD 1
- ALGS 1
- Target Price
- IRD $8.00
- ALGS $70.00
- AVG Volume (30 Days)
- IRD 141.6K
- ALGS 208.8K
- Earning Date
- IRD 03-25-2025
- ALGS 03-10-2025
- Dividend Yield
- IRD N/A
- ALGS N/A
- EPS Growth
- IRD N/A
- ALGS N/A
- EPS
- IRD N/A
- ALGS N/A
- Revenue
- IRD $8,381,000.00
- ALGS $3,945,000.00
- Revenue This Year
- IRD N/A
- ALGS N/A
- Revenue Next Year
- IRD $29.37
- ALGS N/A
- P/E Ratio
- IRD N/A
- ALGS N/A
- Revenue Growth
- IRD N/A
- ALGS N/A
- 52 Week Low
- IRD $0.81
- ALGS $6.76
- 52 Week High
- IRD $2.34
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- IRD N/A
- ALGS 22.89
- Support Level
- IRD N/A
- ALGS $9.51
- Resistance Level
- IRD N/A
- ALGS $11.17
- Average True Range (ATR)
- IRD 0.00
- ALGS 1.65
- MACD
- IRD 0.00
- ALGS -0.27
- Stochastic Oscillator
- IRD 0.00
- ALGS 8.12
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.